Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study

BACKGROUND: Current treatment options for human epidermal growth factor receptor 2 (HER2)‐overexpressing gastric cancer at third‐line have shown limited clinical benefit. Further, there is no specific treatment for HER2 immunohistochemistry (IHC) 2+ and fluorescence in‐situ hybridization‐negative pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Zhi, Liu, Tianshu, Wei, Jia, Wang, Airong, He, Yifu, Yang, Liuzhong, Zhang, Xizhi, Fan, Nanfeng, Luo, Suxia, Li, Zhen, Gu, Kangsheng, Lu, Jianwei, Xu, Jianming, Fan, Qingxia, Xu, Ruihua, Zhang, Liangming, Li, Enxiao, Sun, Yuping, Yu, Guohua, Bai, Chunmei, Liu, Yong, Zeng, Jiangzheng, Ying, Jieer, Liang, Xinjun, Xu, Nong, Gao, Chao, Shu, Yongqian, Ma, Dong, Dai, Guanghai, Li, Shengmian, Deng, Ting, Cui, Yuehong, Fang, Jianmin, Ba, Yi, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626607/
https://www.ncbi.nlm.nih.gov/pubmed/34665942
http://dx.doi.org/10.1002/cac2.12214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626607/
https://www.ncbi.nlm.nih.gov/pubmed/34665942
http://dx.doi.org/10.1002/cac2.12214

Ejemplares similares